Critical review of antipsychotic polypharmacy in the treatment of schizophrenia

International Journal of Neuropsychopharmacology

Volumn 17, Issue 7, 2014, Pages 1083-1093

  Fleischhacker, W Wolfgang ^a   Uchida, Hiroyuki ^b,c  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

Add on treatment; adjunctive treatment; antipsychotic; combination; polypharmacy; schizophrenia

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEUROLEPTIC AGENT; OLANZAPINE; PROLACTIN; QUETIAPINE; RISPERIDONE; SULPIRIDE; TRIACYLGLYCEROL; ZIPRASIDONE; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

BODY MASS; BRIEF PSYCHIATRIC RATING SCALE; CHOLESTEROL BLOOD LEVEL; CHRONIC DISEASE; CLINICAL GLOBAL IMPRESSION SCALE; COGNITIVE DEFECT; DIABETES MELLITUS; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; GLOBAL ASSESSMENT OF FUNCTIONING; HUMAN; HYPERTENSION; IRELAND; LONG TERM CARE; MEDICATION COMPLIANCE; META ANALYSIS (TOPIC); MONOTHERAPY; NEGATIVE SYNDROME; PHYSICIAN ATTITUDE; POLYPHARMACY; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCHIATRIST; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHIZOPHRENIA; SOCIAL INTERACTION; SUDDEN CARDIAC DEATH; SYSTEMATIC REVIEW (TOPIC); TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN; WEIGHT REDUCTION; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC);

ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS AS TOPIC; CLOZAPINE; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PIPERAZINES; POLYPHARMACY; QUINOLONES; SCHIZOPHRENIA;

EID: 84901476875     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145712000399     Document Type: Review

References (71)

1. Addington D, Bouchard R, Goldberg J, Honer B, et al. (2005). Clinical practice guidelines: treatment of schizophrenia. Canadian Journal of Psychiatry 50 (13 Suppl. 1), 7S-57S.
2. Akdede BB, Anil Yagcioglu AE, Alptekin K, Turgut TI, et al. (2006). A double-blind study of combination of clozapine with risperidone in patients with schizophrenia : effects on cognition. Journal of Clinical Psychiatry 67, 1912-1919.
3. Anil Yagcioglu AE, Kivircik Akdede BB, Turgut TI, Tumuklu M, et al. (2005). A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. Journal of Clinical Psychiatry 66, 63-72.
4. Argo TR, Crismon ML, Miller AL, Moore TA, et al. (2008). Texas Medication Algorithm Project Procedural Manual: Schizophrenia Algorithm. Austin, TX: Texas Department of State Health Services.
5. Baandrup L, Allerup P, Lublin H, Nordentoft M, et al. (2010a). Evaluation of a multifaceted intervention to limit excessive antipsychotic co-prescribing in schizophrenia out-patients. Acta Psychiatrica Scandinavica 122, 367-374.
6. Baandrup L, Gasse C, Jensen VD, Glenthoj BY, et al. (2010b). Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia : a population-based nested case-control study. Journal of Clinical Psychiatry 71, 103-108.
7. Baandrup L, Sorensen J, Lublin H, Nordentoft M, et al. (2011). Association of antipsychotic polypharmacy with health service cost : a register-based cost analysis. European Journal of Health Economics. Published online 31 March 2011. doi :10.1007/s10198-011-0308-0.
8. Benner JS, Chapman RH, Petrilla AA, Tang SS, et al. (2009). Association between prescription burden and medication adherence in patients initiating antihypertensive and lipid-lowering therapy. American Journal of Health-System Pharmacy 66, 1471-1477.
9. Biancosino B, Barbui C, Marmai L, Dona S, et al. (2005). Determinants of antipsychotic polypharmacy in psychiatric inpatients : a prospective study. International Clinical Psychopharmacology 20, 305-309.
10. Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, et al. (2010). The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophrenia Bulletin 36, 71-93.
11. Centorrino F, Goren JL, Hennen J, Salvatore P, et al. (2004). Multiple vs single antipsychotic agents for hospitalized psychiatric patients : case-control study of risks vs benefits. American Journal of Psychiatry 161, 700-706.
12. Chakos MH, Glick ID, Miller AL, Hamner MB, et al. (2006). Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial. Psychiatric Services 57, 1094-1101.
13. Chang JS, Ahn YM, Park HJ, Lee KY, et al. (2008). Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. Journal of Clinical Psychiatry 69, 720-731.
14. Chen CK, Huang YS, Ree SC, Hsiao CC (2010). Differential add-on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics. Progress in Neuropsychopharmacology and Biological Psychiatry 34, 1495-1499.
15. Chen RS, Nadkarni PM, Levin FL, Miller PL, et al. (2000). Using a computer database to monitor compliance with pharmacotherapeutic guidelines for schizophrenia. Psychiatric Services 51, 791-794.
16. Cipriani A, Boso M, Barbui C (2009). Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. Cochrane Database of Systematic Reviews, CD006324.
17. Correll CU, Rummel-Kluge C, Corves C, Kane JM, et al. (2009). Antipsychotic combinations vs monotherapy in schizophrenia : a meta-analysis of randomized controlled trials. Schizophrenia Bulletin 35, 443-457.
18. Correll CU, Shaikh L, Gallego JA, Nachbar J, et al. (2011). Antipsychotic polypharmacy: a survey study of prescriber attitudes, knowledge and behavior. Schizophrenia Research 131, 58-62.
19. Edlinger M, Hausmann A, Kemmler G, Kurz M, et al. (2005). Trends in the pharmacological treatment of patients with schizophrenia over a 12 year observation period. Schizophrenia Research 77, 25-34.
20. Essock SM, Schooler NR, Stroup TS, McEvoy JP, et al. (2011). Effectiveness of switching from antipsychotic polypharmacy to monotherapy. American Journal of Psychiatry 168, 702-708.
21. Falkai P, Wobrock T, Lieberman J, Glenthoj B, et al. (2005). World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia. World Journal of Biological Psychiatry 6, 132-191.
22. Fleischhacker WW, Heikkinen ME, Olie JP, Landsberg W, et al. (2010). Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. International Journal of Neuropsychopharmacology 13, 1115-1125.
23. Freudenreich O, Henderson DC, Walsh JP, Culhane MA, et al. (2007). Risperidone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled trial. Schizophrenia Research 92, 90-94.
24. Ganguly R, Kotzan JA, Miller LS, Kennedy K, et al. (2004). Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000. Journal of Clinical Psychiatry 65, 1377-1388.
25. Gilmer TP, Dolder CR, Folsom DP, Mastin W, et al. (2007). Antipsychotic polypharmacy trends among Medicaid beneficiaries with schizophrenia in San Diego County, 1999-2004. Psychiatric Services 58, 1007-1010.
26. Grech P, Taylor D (2012). Long-term antipsychotic polypharmacy-how does it start, why does it continue? Psychopathology 2, 5-11.
27. Haro JM, Edgell ET, Jones PB, Alonso J, et al. (2003). The European Schizophrenia Outpatient Health Outcomes (SOHO) study: rationale, methods and recruitment. Acta Psychiatrica Scandinavica 107, 222-232.
28. Hazra M, Uchida H, Sproule B, Remington G, et al. (2011). Impact of feedback from pharmacists in reducing antipsychotic polypharmacy in schizophrenia. Psychiatry and Clinical Neurosciences 65, 676-678.
29. Henderson DC, Fan X, Copeland PM, Sharma B, et al. (2009). Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients. Journal of Clinical Psychopharmacology 29, 165-169.
30. Honer WG, Thornton AE, Chen EY, Chan RC, et al. (2006). Clozapine alone vs clozapine and risperidone with refractory schizophrenia. New England Journal of Medicine 354, 472-482.
31. Ito H, Koyama A, Higuchi T (2005). Polypharmacy and excessive dosing: psychiatrists' perceptions of antipsychotic drug prescription. British Journal of Psychiatry 187, 243-247.
32. Japanese Society of Psychiatry and Neurology (2008). Treatment Guidelines for Schizophrenia, the Second Edition. Tokyo: Igaku Shoin [in Japanese].
33. Jeste DV, CaligiuriMP, Paulsen JS, Heaton RK, et al. (1995). Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients. Archives of General Psychiatry 52, 756-765.
34. Josiassen RC, Joseph A, Kohegyi E, Stokes S, et al. (2005). Clozapine augmented with risperidone in the treatment of schizophrenia : a randomized, double-blind, placebo-controlled trial. American Journal of Psychiatry 162, 130-136.
35. Joukamaa M, Heliovaara M, Knekt P, Aromaa A, et al. (2006). Schizophrenia, neuroleptic medication and mortality. British Journal of Psychiatry 188, 122-127.
36. Kane JM, Correll CU, Goff DC, Kirkpatrick B, et al. (2009). A multicenter, randomized, double-blind, placebocontrolled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. Journal of Clinical Psychiatry 70, 1348-1357.
37. Koen L, Magni P, Niehaus DJ, le Roux A (2008). Antipsychotic prescription patterns in Xhosa patients with schizophrenia or schizoaffective disorder. African Journal of Psychiatry 11, 287-290.
38. Laska E, Siegel C, Simpson G (1980). Automated review system for orders of psychotropic drugs. Archives of General Psychiatry 37, 824-827.
39. Lemmens P, Brecher M, Van Baelen B (1999). A combined analysis of double-blind studies with risperidone vsplacebo and other antipsychotic agents: factors associated with extrapyramidal symptoms. Acta Psychiatrica Scandinavica 99, 160-170.
40. Leslie DL, Rosenheck RA (2004). Adherence of schizophrenia pharmacotherapy to published treatment recommendations : patient, facility, and provider predictors. Schizophrenia Bulletin 30, 649-658.
41. Morrato EH, Dodd S, Oderda G, Haxby DG, et al. (2007). Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003. Clinical Therapeutics 29, 183-195.
42. National Collaborating Centre for Mental Health (2010). The NICE Guidelines on Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care (update). London: The British Psychological Society and the Royal College of Psychiatrists.
43. Nielsen J, le Quach P, Emborg C, Foldager L, et al. (2010). 10-year trends in the treatment and outcomes of patients with first-episode schizophrenia. Acta Psychiatrica Scandinavica 122, 356-366.
44. Novick D, Haro JM, Suarez D, Vieta E, et al. (2009). Recovery in the outpatient setting : 36-month results from the Schizophrenia Outpatients Health Outcomes (SOHO) study. Schizophrenia Research 108, 223-230.
45. Paton C, Barnes TR, Cavanagh MR, Taylor D, et al. (2008). High-dose and combination antipsychotic prescribing in acute adult wards in the UK: the challenges posed by p.r.n. prescribing. British Journal of Psychiatry 192, 435-439.
46. Paton C, Lelliott P, Harrington M, Okocha C, et al. (2003). Patterns of antipsychotic and anticholinergic prescribing for hospital inpatients. Journal of Psychopharmacology 17, 223-229.
47. Paton C, Whittington C, Barnes TR (2007). Augmentation with a second antipsychotic in patients with schizophrenia who partially respond to clozapine: a meta-analysis. Journal of Clinical Psychopharmacology 27, 198-204.
48. Philip NS, Mello K, Carpenter LL, Tyrka AR, et al. (2008). Patterns of quetiapine use in psychiatric inpatients : an examination of off-label use. Annals of Clinical Psychiatry 20, 15-20.
49. Procyshyn RM, Honer WG, Wu TK, Ko RW, et al. (2010). Persistent antipsychotic polypharmacy and excessive dosing in the community psychiatric treatment setting : a review of medication profiles in 435 Canadian outpatients. Journal of Clinical Psychiatry 71, 566-573.
50. Ray WA, Chung CP, Murray KT, Hall K, et al. (2009). Atypical antipsychotic drugs and the risk of sudden cardiac death. New England Journal of Medicine 360, 225-235.
51. Royal Australian and New Zealand College of Psychiatrists (2005). Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Australian and New Zealand Journal of Psychiatry 39, 1-30.
52. Sakurai H, Bies RR, Stroup ST, Keefe RS, et al. (2012). Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data. Schizophrenia Bulletin. Published online 30 January 2012. doi :10.1093/schbul/sbr189.
53. Santone G, Bellantuono C, Rucci P, Picardi A, et al. (2011). Patient characteristics and process factors associated with antipsychotic polypharmacy in a nationwide sample of psychiatric inpatients in Italy. Pharmacoepidemiology and Drug Safety 20, 441-449.
54. Sernyak MJ, Dausey D, Desai R, Rosenheck R (2003). Prescribers' nonadherence to treatment guidelines for schizophrenia when prescribing neuroleptics. Psychiatric Services 54, 246-248.
55. Sernyak MJ, Rosenheck R (2004). Clinicians' reasons for antipsychotic coprescribing. Journal of Clinical Psychiatry 65, 1597-1600.
56. Shiloh R, Zemishlany Z, Aizenberg D, Radwan M, et al. (1997). Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A doubleblind, placebo-controlled study. British Journal of Psychiatry 171, 569-573.
57. Shim JC, Shin JG, Kelly DL, Jung DU, et al. (2007). Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. American Journal of Psychiatry 164, 1404-1410.
58. Sim K, Su A, Fujii S, Yang SY, et al. (2004). Antipsychotic polypharmacy in patients with schizophrenia : a multicentre comparative study in East Asia. British Journal of Clinical Pharmacology 58, 178-183.
59. Stahl SM, Grady MM (2006). High-cost use of secondgeneration antipsychotics under California's Medicaid program. Psychiatric Services 57, 127-129.
60. Stroup TS, McEvoy JP, Ring KD, Hamer RH, et al. (2011). A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk : comparison of antipsychotics for metabolic problems (CAMP). American Journal of Psychiatry 168, 947-956.
61. Suzuki T, Uchida H, Tanaka KF, Nomura K, et al. (2004). Revising polypharmacy to a single antipsychotic regimen for patients with chronic schizophrenia. International Journal of Neuropsychopharmacology 7, 133-142.
62. Thompson A, Sullivan SA, Barley M, Strange SO, et al. (2008). The DEBIT trial : an intervention to reduce antipsychotic polypharmacy prescribing in adult psychiatry wards-a cluster randomized controlled trial. Psychological Medicine 38, 705-715.
63. Tsutsumi C, Uchida H, Suzuki T, Watanabe K, et al. (2011). The evolution of antipsychotic switch and polypharmacy in natural practice-a longitudinal perspective. Schizophrenia Research 130, 40-46.
64. Uchida H, Suzuki T, Takeuchi H, Arenovich T, et al. (2011). Low dose vs standard dose of antipsychotics for relapse prevention in schizophrenia : meta-analysis. Schizophrenia Bulletin 37, 788-799.
65. Urichuk L, Prior TI, Dursun S, Baker G (2008). Metabolism of atypical antipsychotics : involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Current Drug Metabolism 9, 410-418.
66. van Bruggen R, Gorter K, Stolk RP, Zuithoff P, et al. (2009). Refill adherence and polypharmacy among patients with type 2 diabetes in general practice. Pharmacoepidemiology and Drug Safety 18, 983-991.
67. Waddington JL, Youssef HA, Kinsella A (1998). Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. British Journal of Psychiatry 173, 325-329.
68. Xiang YT, Weng YZ, Leung CM, Tang WK, et al. (2007). Clinical and social determinants of antipsychotic polypharmacy for Chinese patients with schizophrenia. Pharmacopsychiatry 40, 47-52.
69. Yasui-Furukori N, Furukori H, Sugawara N, Fujii A, et al. (2010). Dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia. Journal of Clinical Psychopharmacology 30, 596-599.
70. Zhu B, Ascher-Svanum H, Faries DE, Correll CU, et al. (2008). Cost of antipsychotic polypharmacy in the treatment of schizophrenia. BMC Psychiatry 8, 19.
71. Zink M, Kuwilsky A, Krumm B, Dressing H (2009). Efficacy and tolerability of ziprasidone vs risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial. Journal of Psychopharmacology 23, 305-314.